For fatty liver disease, semaglutide now has the strongest evidence of any GLP-1 medication, and as of August 2025 it is the first GLP-1 with FDA approval specifically for liver disease. Tirzepatide has impressive earlier-phase liver data as well. This guide walks through what each option shows for the condition now called MASLD (formerly NAFLD) and its more serious form MASH (formerly NASH).
Can GLP-1 help fatty liver?
Yes, and for semaglutide this is now backed by a large Phase 3 trial. In the ESSENCE trial (published in the New England Journal of Medicine in 2025), 62.9% of people with MASH and moderate-to-advanced fibrosis who took semaglutide 2.4 mg achieved resolution of steatohepatitis without worsening fibrosis, compared with 34.3% on placebo. Liver fibrosis improved in 36.8% versus 22.4% on placebo. On the strength of those results, the FDA granted accelerated approval to Wegovy (semaglutide 2.4 mg) for MASH with moderate-to-advanced fibrosis on August 15, 2025. GLP-1 medications help the liver largely by driving weight loss and improving insulin resistance, the main metabolic drivers of fat buildup in the liver.
What is the best GLP-1 for fatty liver?
Semaglutide is the best-evidenced choice today because it has the Phase 3 ESSENCE data and an FDA approval for MASH. Tirzepatide (a dual GIP/GLP-1 medicine) is a strong contender on the data: in the Phase 2 SYNERGY-NASH trial (NEJM 2024), up to 73.3% of participants on the 15 mg dose achieved MASH resolution without worsening fibrosis, versus 13.2% on placebo, and more than half improved fibrosis at 52 weeks. Tirzepatide does not yet have a dedicated FDA approval for MASH, so semaglutide leads on regulatory status while tirzepatide leads on raw weight-loss magnitude.
Does GLP-1 help fatty liver without diabetes?
Yes. The benefit for the liver is tied to weight loss and metabolic improvement, not to diabetes status. The ESSENCE participants included people with and without type 2 diabetes, and the liver benefits held. You do not need to be diabetic to have MASLD or to benefit from a GLP-1 if you and your clinician decide it is appropriate. Losing 5 to 10% of body weight reduces liver fat, and roughly 10% or more is associated with steatohepatitis improvement.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Can GLP-1 reverse liver fibrosis?
The ESSENCE trial is notable because it showed improvement in fibrosis, not just resolution of inflammation. About 37% of semaglutide-treated patients improved fibrosis by at least one stage without worsening MASH, versus about 22% on placebo. That is meaningful, but it is not a guarantee of reversal for any individual, and advanced cirrhosis was not the population studied. Fibrosis change is slow and measured over many months, so improvement, when it happens, is gradual.
Comparison: GLP-1 options for fatty liver
| Medication | Type | Liver evidence | FDA status for MASH |
|---|---|---|---|
| Semaglutide | GLP-1 | Phase 3 ESSENCE: 62.9% MASH resolution, fibrosis improvement | Approved (Wegovy, Aug 2025) |
| Tirzepatide | GIP/GLP-1 | Phase 2 SYNERGY-NASH: up to 73.3% MASH resolution | Not yet approved for MASH |
| Liraglutide | GLP-1 | Earlier LEAN trial showed MASH resolution benefit | Not approved for MASH |
| Dulaglutide | GLP-1 | Smaller studies show liver enzyme improvement | Not approved for MASH |
| Exenatide | GLP-1 | Limited liver-specific data | Not approved for MASH |
How much weight loss is needed for liver benefits?
The commonly cited thresholds are about 5% body weight loss to reduce liver fat, around 7 to 10% to improve inflammation, and 10% or more to give the best chance of MASH resolution and fibrosis improvement. GLP-1 medications are well suited to reaching these targets because they produce larger, more sustained weight loss than diet alone for many people. In ESSENCE, semaglutide produced an average 10.5% body weight reduction at 72 weeks.
How does FormBlends fit in?
FormBlends offers physician-supervised compounded semaglutide and tirzepatide for weight management. Because the liver benefit of these medicines runs through weight loss and metabolic improvement, a supervised GLP-1 program can be relevant if your clinician determines weight loss is appropriate for your MASLD. Compounded semaglutide and tirzepatide are not FDA-approved products and are not the same as the brand-name MASH approval; any liver-specific treatment decision should be made with a clinician who can monitor your liver and overall health.
Frequently asked questions
Can GLP-1 help fatty liver?
Yes. Semaglutide showed resolution of steatohepatitis and fibrosis improvement in the Phase 3 ESSENCE trial and is FDA-approved for MASH with fibrosis as of August 2025.
What is the best GLP-1 for fatty liver?
Semaglutide has the strongest evidence and an FDA approval for MASH. Tirzepatide has strong Phase 2 data but is not yet approved for liver disease.
Does GLP-1 help fatty liver without diabetes?
Yes. The liver benefit is driven by weight loss and metabolic improvement, which apply whether or not you have diabetes.
Can GLP-1 reverse liver fibrosis?
ESSENCE showed fibrosis improvement in about 37% of semaglutide patients versus 22% on placebo. Improvement is possible but gradual and not guaranteed for everyone.
How much weight do I need to lose to help my liver?
About 5% reduces liver fat, 7 to 10% improves inflammation, and 10% or more gives the best chance of MASH resolution.
Are compounded GLP-1 medications the same as brand-name for the liver?
No. Compounded versions are not FDA-approved and the MASH approval applies to the brand product. Discuss any liver-focused use with your clinician.
What is MASLD and MASH?
MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) is fat buildup in the liver. MASH (formerly NASH) is the inflammatory form with liver cell damage and possible fibrosis.
Related guides
- GLP-1 And Liver Health: NAFLD And NASH
- Glp-1 for Nash Fatty Liver: Evidence and Considerations
- Glp-1 and Fatty Liver Nash Treatment
- Semaglutide for Nash Fatty Liver: Evidence and Considerations
- Tirzepatide for Nash Fatty Liver: Evidence and Considerations
- Retatrutide for Nash Fatty Liver Treatment
Sources
- Phase 3 ESSENCE trial of semaglutide in MASH, New England Journal of Medicine, 2025: https://www.nejm.org/doi/full/10.1056/NEJMoa2413258
- FDA approves semaglutide (Wegovy) for MASH with fibrosis, Aug 2025 coverage: https://www.ajmc.com/view/fda-approves-semaglutide-for-mash-with-fibrosis
- SYNERGY-NASH tirzepatide trial, New England Journal of Medicine, 2024: https://www.nejm.org/doi/abs/10.1056/NEJMoa2401943
- AASLD Practice Guidance on semaglutide for MASH, 2025: https://journals.lww.com/hep/fulltext/2026/05000/semaglutide_therapy_for_metabolic.28.aspx
- NIH NIDDK, MASLD/NAFLD overview: https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →